德谷门冬双胰岛素治疗中国2型糖尿病患者的成本-效果分析

打开文本图片集

中图分类号 R956；R977.1+5 文献标志码 A 文章编号 1001-0408（2025）22-2809-06

DOI 10.6039/j.issn.1001-0408.2025.22.10

ABSTRACTOBJECTIVEToevaluatethelong-termcost-effectivenessof insulin degludecand insulinaspart （IDegAsp）in patientswith type2 diabetes melltus（T2DM）inChina.METHODSAcost-efectiveness analysiswasconductedfromthe perspectiveofteChinesehealthcaresystem，usingtheCOREdiabetes modeltosimulatelong-term（20-year）healthandeconomic outcomes.BaselinecohortcharacteristicsandtreatmenteffectdatawerederivedfromtheCREATEstudy.Thepricesofglucoseloweringdrugs wereobtainedfrommedicalinsurancepaymentstandardsandtheaveragewinningbidpricesinthefollow-upround of the spcializedcentralized procurementfor insulin，whilethedailydosages werederivedfromthe CREATEstudy.Thecostsof complications and utility values were obtained from published literature，with a discount rate of 5% . One-way sensitivity analysis， scenarioanalysisandprobabilsticsensitivityanalysiswereperformedtoverifytherobustnessoftheresultsRESULTSPatients switchingfrompreviousonce-dailybasalinsulinregimens toIDegAsptherapygainedanincrementalO.190quality-adjustedlifeyear （QALY）withdirect medical costsavings of 42163.58 yuan.For those switching from premixed insulin therapies，IDegAsp treatmentprovidedO.130incrementalQALYandreduceddirecthealthcarecostsby41129.11yuan.Theoutcomewassignificantly influencedbythediscountrateandthecostofcomplications.Probabilisticsensitvityanalysisandscenarioanalysisconfimdthe robustness of thesefindings.CONCLUsIONsSwitching frompreviousdailybasal insulinorpremixedinsulinregimensto IDegAsp inChinesepatientswithT2DMcanimprovepatients’long-termhealthoutcomesandachievecostsavings，makingita more cost-effective treatment option.

KEYWORDSinsulindegludecandinsulinaspart；dailybasal insulin；premixedinsulin；cost-efectivenessanalysis；type2 diabetesmellitus；real-world data

根据WHO糖尿病病因学分型体系，糖尿病可分为1型糖尿病、2型糖尿病（type2diabetesmellitus，T2DM）、特殊类型糖尿病和妊娠期糖尿病。（剩余12173字）